Back to library
Weight Management

Semaglutide

A GLP-1 receptor agonist used for weight management and blood sugar control. Originally developed for type 2 diabetes. DO NOT combine with Tirzepatide or other GLP-1 agonists.

3 mg vialHalf-life: 7 daysOnce weeklyHigh-conc · ≤20 mg/mL
Order: Coming soon

Overview

Clinical Benefits
  • Significant weight loss
  • Appetite suppression
  • Blood sugar control
  • Cardiovascular benefits
Administration

Subcutaneous injection — abdomen, thigh, or upper arm

Drug class: glp1 agonist

Clinical Dosing

Typical dosage
0.25mg starting, titrate up to 2.4mg
Starting dose
0.25mg
Cadence
Once weekly
Full titration schedule
PhaseDose
Weeks 1-40.25mg once weekly
Weeks 5-80.5mg once weekly
Weeks 9-121.0mg once weekly
Weeks 13-161.7mg once weekly
Weeks 17+2.4mg once weekly (maintenance)

Safety Profile

Side effects
  • • Nausea (most common at dose increases)
  • • Vomiting
  • • Diarrhea
  • • Constipation
Contraindications
  • • Medullary thyroid carcinoma
  • • MEN 2 syndrome
  • • Pancreatitis history
Do not combine with

Frequently asked questions

Semaglutide is most commonly researched for: Significant weight loss, Appetite suppression, Blood sugar control, Cardiovascular benefits.

Ready to build a protocol with Semaglutide?

LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.

You’ll be asked to sign in first. Free tier includes the chat preview.

Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.

Add to Home Screen

Install PeptideAI for quick access and an app-like experience.